213 related articles for article (PubMed ID: 26403559)
1. Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.
Masuyer G; Douglas RG; Sturrock ED; Acharya KR
Sci Rep; 2015 Sep; 5():13742. PubMed ID: 26403559
[TBL] [Abstract][Full Text] [Related]
2. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
Douglas RG; Ehlers MR; Sturrock ED
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.
Masuyer G; Schwager SL; Sturrock ED; Isaac RE; Acharya KR
Sci Rep; 2012; 2():717. PubMed ID: 23056909
[TBL] [Abstract][Full Text] [Related]
4. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.
Douglas RG; Sharma RK; Masuyer G; Lubbe L; Zamora I; Acharya KR; Chibale K; Sturrock ED
Clin Sci (Lond); 2014 Feb; 126(4):305-13. PubMed ID: 24015848
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
Kumar N; Yin C
Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
[TBL] [Abstract][Full Text] [Related]
7. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
[TBL] [Abstract][Full Text] [Related]
8. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
10. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.
Masuyer G; Akif M; Czarny B; Beau F; Schwager SL; Sturrock ED; Isaac RE; Dive V; Acharya KR
FEBS J; 2014 Feb; 281(3):943-56. PubMed ID: 24289879
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
Hrenak J; Paulis L; Simko F
Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
[TBL] [Abstract][Full Text] [Related]
12. Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools.
Alfaro S; Navarro-Retamal C; Caballero J
Mini Rev Med Chem; 2020; 20(14):1436-1446. PubMed ID: 31889494
[TBL] [Abstract][Full Text] [Related]
13. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis attenuates pulmonary fibrosis in silicotic rats.
Gao X; Xu H; Zhang B; Tao T; Liu Y; Xu D; Cai W; Wei Z; Li S; Zhang H; Mao N; Zhang G; Li D; Jin F; Li S; Zhang L; Liu H; Hao X; Yang F
Exp Physiol; 2019 Oct; 104(10):1562-1574. PubMed ID: 31290182
[TBL] [Abstract][Full Text] [Related]
14. A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.
Danilov SM; Wade MS; Schwager SL; Douglas RG; Nesterovitch AB; Popova IA; Hogarth KD; Bhardwaj N; Schwartz DE; Sturrock ED; Garcia JG
PLoS One; 2014; 9(2):e88001. PubMed ID: 24505347
[TBL] [Abstract][Full Text] [Related]
15. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
16. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
[TBL] [Abstract][Full Text] [Related]
17. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
18. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
20. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
